

Special Issue

Medico-Legal and Bioethical Implications of Infectious Disease Epidemiology and Control Strategies

Message from the Guest Editors

As recently declared by the World Health Organization, the end of the pandemic COVID-19 is "in sight". It is undeniable that the pandemic caught the health systems of the world unprepared, even the most economically viable. The delicate epidemiological situation that we have faced necessarily constitutes, on the one hand, an opportunity to discuss the bioethical and medico-legal implications of the management and preventive strategies adopted, and, on the other hand, a starting point for formulating strategies and protocols useful for coping with infectious diseases. Hence, this Special Issue of *Vaccines*, entitled "Medico-Legal and Bioethical Implications of Infectious Disease Epidemiology and Control Strategies", aims to open a scientific debate on bioethical and medico-legal issues related to the prevention and management of infectious diseases, as well as possible new applicable strategies.

Guest Editors

Dr. Andrea Cioffi

Department of Clinical and Experimental Medicine, Section of Legal Medicine, University of Foggia, 71122 Foggia, Italy

Dr. Camilla Cecanneccchia

Department of Anatomical, Histological, Forensic and Orthopaedic Sciences, Sapienza University of Rome, 00185 Rome, Italy



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4

CiteScore 9.9

Indexed in PubMed



mdpi.com/si/157328

Vaccines

Editorial Office

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34

vaccines@mdpi.com

[mdpi.com/journal/](https://mdpi.com/journal/vaccines)

[vaccines](https://mdpi.com/journal/vaccines)

Deadline for manuscript submissions

closed (25 November 2023)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](http://mdpi.com/journal/vaccines)

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

